Real-Time Split-Dose PET/CT-Guided Ablation Improves Colorectal Liver Metastasis Detection and Ablation Zone Margin Assessments without the Need for Repeated Contrast Injection
Authors:
- Mahdi Zirakchian ZadehMZMahdi Zirakchian Zadeh
- Randy YehRYRandy Yeh
- Henry S. KuninHKHenry S. Kunin
- Assen S. KirovAKAssen S. Kirov
- Elena N. PetreEPElena N. Petre
- Mithat GönenMGMithat Gönen
- Mikhail SilkMSMikhail Silk
- Francois H. CornelisFrancois H. Cornelis
- Kevin C. SoaresKSKevin C. Soares
- Etay ZivEZEtay Ziv
- Stephen B. SolomonSSStephen B. Solomon
- Vlasios S. SotirchosVSVlasios S. Sotirchos
Open Access
Abstract
Background: Real-time split-dose PET can identify the targeted colorectal liver metastasis (CLM) and eliminate the need for repeated contrast administration before and during thermal ablation (TA). This study aimed to assess the added value of pre-ablation real-time split-dose PET when combined with non-contract CT in the detection of CLM for ablation and the evaluation of the ablation zone and margins. Methods: A total of 190 CLMs/125 participants from two IRB-approved prospective clinical trials using PET/CT-guided TA were analyzed. Based on detection on pre-TA imaging, CLMs were categorized as detectable, non-detectable, and of poor conspicuity on CT alone, and detectable, non-detectable, and low FDG-avidity on PET/CT after the initial dose. Ablation margins around the targeted CLM were evaluated using a 3D volumetric approach. Results: We found that 129/190 (67.9%) CLMs were detectable on CT alone, and 61/190 CLMs (32.1%) were undetectable or of poor conspicuity, not allowing accurate depiction and targeting by CT alone. Thus, the theoretical 5- and 10-mm margins could not be defined in these tumors (32.1%) using CT alone. When TA intraprocedural PET/CT images are obtained and inspected (fused PET/CT), only 4 CLM (2.1%) remained undetectable or had a low FDG avidity. Conclusions: The addition of PET to non-contrast CT improved CLM detection for ablation targeting, margin assessments, and continuous depiction of the FDG avid CLMs during the ablation without the need for multiple intravenous contrast injections pre- and intra-procedurally.Keywords
Funding Information
- National Institutes of Health (R01 CA240569-01, R21-CA131763-01A1, P30 CA008748)
- NIH/NCI Cancer Center (R01 CA240569-01, R21-CA131763-01A1, P30 CA008748)
This publication has 35 references indexed in Scilit:
- Split-Dose Technique for FDG PET/CT–guided Percutaneous Ablation: A Method to Facilitate Lesion Targeting and to Provide Immediate Assessment of Treatment EffectivenessRadiology, 2013
- Small Liver Colorectal Metastases Treated with Percutaneous Radiofrequency Ablation: Local Response Rate and Long-term Survival with Up to 10-year Follow-upRadiology, 2012
- Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrenceThe American Journal of Surgery, 2010
- Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysisJournal of Magnetic Resonance Imaging, 2009
- Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer, 2009
- Radiofrequency Ablation of Liver Metastases—Software-Assisted Evaluation of the Ablation Zone in MDCT: Tumor-Free Follow-Up Versus Local Recurrent DiseaseCardioVascular and Interventional Radiology, 2009
- The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRIEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Radiofrequency Ablation versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?Digestive Surgery, 2008
- Local Recurrence After Hepatic Radiofrequency CoagulationAnnals of Surgery, 2005
- The Role of Whole-Body Positron Emission Tomography With [18F]Fluorodeoxyglucose in Identifying Operable Colorectal Cancer Metastases to the LiverArchives of Surgery, 1996